Table 1.
A summary of the drugs that have been developed to target the MET/HGF signalling pathway and their use in clinical trials, with a focus on those which have reached Phase III (completed or ongoing).
| Inhibitor name | Phase III ongoing-completed | |
|---|---|---|
| Anti-HGF monoclonal antibodies | Rilotumumab/AMG-102 | NCT02154490 |
| Ficlatuzumab/AV-299/SCH 900105 | Not yet conducted – trials completed and ongoing at Phase 2 | |
| HuL2G7/TAK701 | Not yet conducted – trial completed at Phase 1, none ongoing | |
| YYB-101 | Not yet conducted – trials completed at Phase 1 and ongoing at Phase 2 | |
| MET antagonists | Onartuzumab/RO5490258/PRO-142966 | NCT02488330, NCT01662869, NCT01887886, NCT02031744 |
| SAIT301 | Not yet conducted – trial completed at Phase 1, none ongoing | |
| Emibetuzumab/LY2875358/LA480 | Not yet conducted – trials completed and ongoing at Phase 2 | |
| Amivantamab/JNJ-61186372/JNJ-372 | NCT04487080 | |
| ABT-700/h224G11 | Not yet conducted – trials completed at Phase 1 and ongoing at Phase 2 | |
| MET kinase inhibitors | Tivantinib/ARQ 197 | NCT02029157, NCT01755767, NCT01244191 |
| Savolitinib/AZD6094/HMPL-504/HMP-504/Volitinib | NCT03091192 | |
| Tepotinib/MSC2156119J/EMD1214063 | Not yet conducted – trials completed at Phase 1 and ongoing at Phase 2 | |
| Glesatinib/MGCD265 | Not yet conducted – trials completed and ongoing at Phase 2 | |
| Capmatinib/INC280 | NCT04427072, NCT03784014 | |
| PHA665752 | Not yet conducted – no trials completed at any Phase | |
| SU11274 | Not yet conducted – no trials completed at any Phase | |
| Foretinib/GSK1363089/ XL880 | Not yet conducted – trials completed and ongoing at Phase 2 | |
| Merestinib/LY2801653 | Not yet conducted – trials completed at Phase 1 and ongoing at Phase 2 | |
| MK8033 | Not yet conducted – trial completed at Phase 1, none ongoing | |
| Multi-kinase inhibitors |
Crizotinib/PF-02341066 Targets: MET, ALK, ROS, RON |
NCT02838420, NCT02075840, NCT01639001, NCT00932893, NCT01154140, NCT04009317, NCT03052608, NCT02737501, NCT02767804, NCT02201992, NCT03194893, NCT03126916, NCT03596866, NCT03874273 |
|
Cabozantinib/XL184, BMS907351 Targets: MET, VEGFR2, KIT, RET, AXL, FLT3 |
NCT01908426, NCT01605227, NCT01865747, NCT00704730, NCT03690388, NCT04338269, NCT03755791, NCT03937219, NCT03375320, NCT04446117, NCT03793166, NCT03729245, NCT03141177, NCT04211337 | |
|
Amuvatinib/MP470 Targets: MET, c-Kit, PDGFRα, Flt3, c-Ret |
Not yet conducted – trial completed at Phase 2, none ongoing |